Growth Metrics

Coherus Oncology (CHRS) Amortizatization of Intangibles (2016 - 2023)

Coherus Oncology (CHRS) has disclosed Amortizatization of Intangibles for 9 consecutive years, with -$428000.0 as the latest value for Q4 2023.

  • Quarterly Amortizatization of Intangibles fell 153.5% to -$428000.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2023, down 74.09% year-over-year, with the annual reading at $4.2 million for FY2024, 72.79% up from the prior year.
  • Amortizatization of Intangibles hit -$428000.0 in Q4 2023 for Coherus Oncology, down from $255000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $3.7 million in Q1 2022 to a low of -$4.2 million in Q4 2021.
  • Historically, Amortizatization of Intangibles has averaged $534950.0 across 5 years, with a median of $408500.0 in 2020.
  • Biggest five-year swings in Amortizatization of Intangibles: surged 451.06% in 2020 and later tumbled 225.67% in 2021.
  • Year by year, Amortizatization of Intangibles stood at $613000.0 in 2019, then soared by 451.06% to $3.4 million in 2020, then crashed by 225.67% to -$4.2 million in 2021, then skyrocketed by 118.85% to $800000.0 in 2022, then tumbled by 153.5% to -$428000.0 in 2023.
  • Business Quant data shows Amortizatization of Intangibles for CHRS at -$428000.0 in Q4 2023, $255000.0 in Q3 2023, and $243000.0 in Q2 2023.